Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis

NCT01453764 | Withdrawn

• 1 other identifier: AD-US-MS-001
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The intent of this clinical study is to answer the questions:

1. 1.Is the proposed treatment safe
2. 2.Is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes?

Conditions

Multiple Sclerosis; Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Nervous System Diseases

Outcome Measures

Primary Outcomes (3)

• Clinical improvement in disability score compared to baseline

  3 months

• Number of patients with adverse events

  The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 6-month period following treatment.

  up to 6 months

• Clinical improvement in disability score compared to baseline

  6 months

Secondary Outcomes (4)

• MS disease activity measured by the number of Gd-enhancing brain MRI lesions

  3 months

• Reduced number of relapses or freedom from progression of disease

  3 months

• Reduced number of relapses or freedom from progression of disease

  6 months

• MS disease activity measured by the number of Gd-enhancing brain MRI lesions

  6 months

Study Arms (1)

Adipose SVF IV Infusion

EXPERIMENTAL

IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion

Procedure: Harvesting and Implantation of SVF

Interventions

Harvesting and Implantation of SVF PROCEDURE

The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.

Adipose SVF IV Infusion

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and Females between Age 18 and 80 years.
• Duration of disease: \>5 years
• Failure to respond or intolerance to the currently available Multiple Sclerosis (MS) immunomodulatory treatments (ie interferons, Copaxone, immunosuppression): the lack of response to these treatments will be determined/defined by either an increase (deterioration) of at least one degree in the Expanded Disability Status Scale (EDSS) score during the last year or the appearance of at least two major relapses of MS during the same period of time (under treatment) or intolerance to these agents.
• Up to date on all age and gender appropriate cancer screening per American Cancer Society .

You may not qualify if:

• Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
• Life expectancy \< 6 months due to concomitant illnesses.
• Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
• Active infectious disease. For patients who have tested positive, an expert will be consulted as to patient eligibility based on the patient's infectious status
• Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
• Patients on chronic immunosuppressive transplant therapy
• Systolic blood pressure (supine) ≤90 mmHg;
• Resting heart rate \> 100 bpm;
• Active clinical infection.
• Cerebrovascular accident within 6 months prior to study entry
• Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
• History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
• Unwilling and/or not able to give written informed consent.

Sponsors & Collaborators

• Ageless Regenerative Institute: lead

Study Sites (1)

Ageless Regenerative Institute LLC

Aventura, Florida, 33180, United States

Location

MeSH Terms

Conditions

Multiple Sclerosis; Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Nervous System Diseases

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Demyelinating Diseases; Immune System Diseases

Study Officials

• Sharon McQuillan, MD

  Ageless Regenerative Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 3, 2011
• First Posted: October 18, 2011
• Study Start: April 1, 2016
• Primary Completion: December 1, 2018
• Study Completion: April 1, 2019
• Last Updated: September 1, 2017

Record last verified: 2017-08

Locations

US (1)